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Abstract
Background: Liver fibrosis in human immunodeficiency virus (HIV)-infected individuals is mostly attributable to co-
infection with hepatitis B or C. The impact of other risk factors, including prolonged exposure to combined
antiretroviral therapy (cART) is poorly understood. Our aim was to determine the prevalence of liver fibrosis and
associated risk factors in HIV-infected individuals based on non-invasive fibrosis assessment using transient
elastography (TE) and serum biomarkers (Fibrotest [FT]).
Methods: In 202 consecutive HIV-infected individuals (159 men; mean age 47 ± 9 years; 35 with hepatitis-C-virus
[HCV] co-infection), TE and FT were performed. Repeat TE examinations were conducted 1 and 2 years after study
inclusion.
Results: Significant liver fibrosis was present in 16% and 29% of patients, respectively, when assessed by TE (≥ 7.1
kPa) and FT (> 0.48). A combination of TE and FT predicted significant fibrosis in 8% of all patients (31% in HIV/
HCV co-infected and 3% in HIV mono-infected individuals). Chronic ALT, AST and g-GT elevation was present in
29%, 20% and 51% of all cART-exposed patients and in 19%, 8% and 45.5% of HIV mono-infected individuals.
Overall, factors independently associated with significant fibrosis as assessed by TE (OR, 95% CI) were co-infection
with HCV (7.29, 1.95-27.34), chronic AST (6.58, 1.30-33.25) and g-GT (5.17, 1.56-17.08) elevation and time on
dideoxynucleoside therapy (1.01, 1.00-1.02). In 68 HIV mono-infected individuals who had repeat TE examinations,
TE values did not differ significantly during a median follow-up time of 24 months (median intra-patient changes
at last TE examination relative to baseline: -0.2 kPa, p = 0.20).
Conclusions: Chronic elevation of liver enzymes was observed in up to 45.5% of HIV mono-infected patients on
cART. However, only a small subset had significant fibrosis as predicted by TE and FT. There was no evidence for
fibrosis progression during follow-up TE examinations.
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Background
Effective and long-term combination antiretroviral ther-
apy (cART) has substantially decreased morbidity and
mortality in human immunodeficiency virus (HIV)
infected individuals [1,2]. The incidence of acquired
immune deficiency syndrome (AIDS)-defining events has
continuously declined over the past years and liver dis-
eases, mainly due to co-infection with the hepatitis C
virus (HCV) and/or hepatitis B virus (HBV) or presence
of metabolic syndrome-associated non-alcoholic steato-
hepatitis have emerged as key issues within the HIV
infected population [2]. In addition, cART-related hepa-
totoxicity may contribute to hepatic injury in both HIV
mono-infected individuals and those with hepatitis co-
infection. Albeit not clearly defined, cART-related hepa-
totoxicity may occur in the context of acute events such
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associated with progressive liver damage resulting in
non-alcoholic steatohepatitis and significant fibrosis [3,4].
In a recent study, chronic alanine aminotransferase
(ALT) elevations have been observed in 16% of HIV
mono-infected individuals during cART but their clinical
significance over time is poorly understood [5].
The effects of long-term cART on liver fibrosis in
patients with or without hepatitis co-infection and the
involvement of the metabolic syndrome continue to be
c o n t r o v e r s i a l l yd i s c u s s e d .W h i l eo nt h eo n eh a n d ,l o n g -
term cART was found to be a protective factor for liver
fibrosis in some studies [6,7], other findings suggest that
exposure to dideoxynucleosides and other nucleoside
analog reverse-transcriptase inhibitors (NRTIs) is asso-
ciated both with chronic elevation of aspartate amino-
transferase (AST) and/or ALT levels and liver fibrosis
[5,8].
Liver biopsy remains the gold standard for the accu-
rate assessment of liver fibrosis. However, the procedure
is invasive and may be associated with severe adverse
events [9]. In addition, sampling errors as well as obser-
ver variability may limit the reliability of the procedure.
Therefore, blood tests (e.g., AST-to-platelet ratio index
[APRI] and Fibrotest [FT]) have been developed to non-
invasively predict the extent of liver fibrosis in a variety
of liver diseases [10,11].
Likewise, transient elastography (TE), an ultrasound-
based method, which estimates liver fibrosis by measur-
ing liver stiffness has become widely available as a quick
and reliable non-invasive means to assess liver fibrosis
[12]. Several studies have shown that there is a good cor-
relation for the prediction of advanced liver fibrosis and
cirrhosis between blood tests, TE and liver histology
[13-17].
In this study, we sought to non-invasively assess the
prevalence of liver fibrosis and associated risk factors in a
cohort of HIV-infected individuals as assessed by TE
alone, FT alone or TE and FT combined.
Methods
Patient population
All patients aged 18 and over with chronic HIV infection
who attended the hepatology outpatient clinic at the J. W.
Goethe University Hospital between December 2008 and
June 2009 were offered non-invasive assessment of liver
fibrosis using TE and blood tests (cross-sectional study).
In addition, all individuals were offered repeat TE mea-
surements at one year (in 2010) and two years (in 2011)
after study inclusion (longitudinal study).
Demographic data, including age, gender, ethnicity, and
BMI (defined as weight in kilograms divided by the
height in meters squared) were recorded for each indivi-
dual patient at baseline in the cross-sectional study. In
addition, most recent virologic data, including hepatitis B
surface antigen (HBsAg) status, HCV antibody status
plus HCV RNA, HIV RNA, and CD4+ T-cell count as
well as detailed history of prior antiretroviral therapy was
also recorded. Patients with known or suspected liver
disease other than HCV and/or HBV and with past or
present alcohol abuse (more than two standard drinks
[13.7 g] for men or 1 standard drink for women per day)
were excluded from the study.
The study was performed in accordance with the
Declaration of Helsinki and was approved by the local
ethics committee. All patients had signed a written
informed consent prior to study inclusion.
Blood tests
Blood tests were performed in all patients after an over-
n i g h tf a s to fa tl e a s t1 2ho nt h es a m ed a yt h a tT Ew a s
performed. The following blood parameters were taken:
AST, ALT, g-glutamyl-transferase (gGT), alkaline phos-
phatase, total bilirubin, platelet count, a2-macroglobulin,
apolipoprotein A1, haptoglobin, glucose, insulin, total cho-
lesterol, triglycerides, and haptoglobin. Enzymatic activity
was measured at 37°C in accordance with the International
Federation of Clinical Chemistry Standards. Serum sam-
ples for insulin determination were immediately refriger-
ated at 4°C and shipped for testing on the same day.
Chronic elevation of liver enzymes was defined as an
ALT, AST or g-GT level greater than the age-adjusted
upper limit of normal at two or more consecutive
semiannual visits, in line with previously recommended
definitions [5].
The commercially available Fibrotest (FT; BioPredic-
tive, Paris, France) was performed using a patented algo-
r i t h mt h a ti n c l u d e sa2-macroglobulin, apolipoprotein
A1, haptoglobin, g-GT and total bilirubin, adjusted for
age and gender [10]. Security algorithms requiring the
exclusion of patients at high risk for false-positive or
false-negative results were respected. Cut-off values for
the diagnosis of significant fibrosis (> 0.48) and cirrhosis
(≥ 0.75) were chosen in line with the manufacturer’s
recommendations.
Finally, the homeostasis model assessment (HOMA)
insulin resistance (IR) index (fasting plasma insulin [μU/
mL] × fasting plasma glucose [mg/dL]/405) was also
recorded in each patient.
Transient elastography (TE)
All TE examinations were performed after an overnight
fast of at least 12 h.
TE (FibroScan
®, Echosens, Paris, France) involves a
probe that includes an ultrasound transducer mounted on
the axis of a vibrator. A vibration wave excited by the
vibrator induces an elastic shear wave that propagates
through the liver tissue. The velocity of these propagations
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liver stiffness. The results are expressed in kilopascals
(kPa) [18].
TE measurements were considered reliable when at
least 10 successful measurements with a success-rate of
at least 60% and an interquartile range of 30% or lower
were achieved, according to the manufacturer’s
instructions.
For statistical analyses, TE results were assigned to dif-
ferent stages of liver fibrosis according to the semiquanti-
tative histological staging system of METAVIR. The
predefined cut-off values were ≥ 7.1 kPa for significant
fibrosis (corresponding to ≥ F2) and ≥ 12.5 kPa for cir-
rhosis (corresponding to ≥ F4) in line with previous
recommendations [19-21].
Combination of noninvasive methods
To improve the diagnostic accuracy of noninvasive meth-
ods, a combination of TE and FT was determined based
on an algorithm recently proposed by Castera and co-
workers (Bordeaux algorithm) [22]. Cut-off values for the
combination of TE and FT were ≥ 7.1 kPa plus > 0.48 for
the detection of significant fibrosis and ≥ 12.5 kPa plus ≥
0.75 for the detection of cirrhosis, respectively.
Statistical analysis
All statistical analyses were carried out using the SPSS
Statistics Software Package for Windows, version 19.0
(SPSS, IBM, Somers, NY, USA) or GraphPad Prism for
Windows, version 4.02 (GraphPad Software, La Jolla, CA,
USA).
Clinical and laboratory characteristics of patients are
g i v e na sm e a n±s t a n d a r dd e v i a t i o no rm e d i a na n d
range, as appropriate.
For categorical variables, the chi-square test or the Fish-
er’s exact test was performed. For continuous variables,
the Student’s t-test or the Mann-Whitney U-test was used.
Intra-group comparisons were made using the Wilcoxon’s
test for paired data. All tests were two-tailed and a p-value
< 0.05 was judged to be statistically significant.
For association analyses, univariate and multivariate
models were employed. Parameters with a p-value <
0.05 in the univariate analysis were included in a multi-
variate logistic regression model based on the backward
stepwise Wald method.
Results
Baseline patient characteristics
In total, 202 individuals with HIV infection had liver
fibrosis assessed by TE and blood tests. The respective
examinations were considered valid in all patients.
The main patient characteristics are summarized in
Table 1. The mean age was 47 ± 9 years. The proportion
of men was 79% (n = 159), and 94% of the subjects were
of Caucasian ethnicity (n = 190). The mean duration of
HIV infection was 13 ± 7 years. The majority of patients
were on antiretroviral therapy (89%, n = 179). The mean
CD4+ T-cell count was 591 ± 254 cells/μla n dp l a s m a
HIV RNA was below the limit of detection in 77% of
patients (n = 156). HCV co-infection was present in 17%
(n = 35; mean duration of infection, 13 ± 5 years) of
patients and 9% (n = 18; mean duration of infection, 15 ±
5 years) were HBsAg positive.
Patients with HIV/HCV co-infection were more often
former iv-drug users (47% vs. 1%, p < 0.0001; data not
shown) and were longer infected with HIV than those
with HIV mono-infection (17 vs. 13 years, p = 0.002). In
addition, HIV/HCV co-infected patients were longer
exposed to dideoxynucleosides (stavudine, didanosine,
or zalcitabine), compared to patients with HIV mono-
infection (49 vs. 28 months, p = 0.048).
Liver fibrosis staging - cross-sectional study
The median liver stiffness in the study population was
4.9 kPa (range, 2.4-36.8; mean ± SD, 6.1 ± 4.5 kPa). In
total, 33 (16%) and 10 (5%) patients had TE values cor-
responding to significant liver fibrosis (≥ 7.1 kPa) and
cirrhosis (≥ 12.5 kPa), respectively.
The main baseline patient characteristics according to
liver stiffness values ≥ 7.1 kPa vs. < 7.1 kPa are shown in
Table 1. Patients with TE values ≥ 7.1 kPa corresponding
to significant (or higher) liver fibrosis were more often
co-infected with HCV than patients with TE values < 7.1
kPa (p < 0.0001). In addition, chronic elevation of ALT
(p = 0.001), AST (p < 0.0001) and g-GT (p = 0.001), high
HOMA-IR (p = 0.006) and cumulative exposure to
dideoxynucleoside therapy (p = 0.006) was more com-
monly observed in patients with presumed significant
fibrosis as compared to those without significant fibrosis.
In contrast, total serum cholesterol levels were lower in
patients with significant fibrosis (p < 0.0001).
According to FT values, significant liver fibrosis (> 0.48)
and cirrhosis (≥ 0.75) were present in 59 (29%) and
16 (8%) patients, respectively.
When both TE and FT were combined, 16 (8%) and 5
(3%) patients had predicted significant fibrosis (≥ 7.1 kPa +
>0 . 4 8 )o rc i r r h o s i s( ≥ 12.5 kPa + ≥ 0.75), respectively.
Finally, after excluding viral hepatitis, only 5 (3%) and 1
(0.6%) remained to have significant fibrosis and cirrhosis
according to the combined tests. On the contrary, 11 (31%)
and 4 (11%) of HIV/HCV co-infected individuals had pre-
dicted significant fibrosis and cirrhosis according to the
test combination.
Chronic elevation of liver enzymes
Chronic elevation of ALT, AST and g-GT levels was
present in 27% (n = 55), 19% (n = 38) and 49% (n = 98)
of all patients, respectively (Table 1). In patients on
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chronic elevated ALT, AST and g-GT levels. After
excluding viral hepatitis (HBV and HCV) in cART-
exposed patients, 19% (n = 25), 8% (n = 11) and 45.5%
(n = 60) still had elevated liver enzymes. Among
patients with chronic g-GT elevation, 45% (n = 41) were
taking the non-nucleoside reverse transcriptase inhibitor
nevirapine, a drug commonly associated with g-GT
elevation.
Baseline characteristics associated with significant liver
fibrosis/cirrhosis as assessed by TE, FT or combination
of the two.
Univariate analysis (OR [95% CI] showed that co-infec-
tion with HCV (12.98 [5.49-30.71]), chronic elevation of
ALT (3.66 [1.69-7.93]), AST (10.71 [4.63-24.80]) and g-
GT (4.11 [1.75-9.64]) and cumulative exposure to certain
antiretrovirals including protease inhibitors (1.00 [1.00-
1.04]) and dideoxynucleosides (1.01 [1.00-1.02]) were all
associated with significant liver fibrosis as measured by
TE alone. Furthermore, metabolic factors such as high
HOMA-IR (1.28 [1.09-1.49]), high BMI (1.17 [1.04-1.33])
and low serum cholesterol (0.98 [0.97-0.99]) were also
associated with liver stiffness ≥ 7.1 kPa. Factors that
remained independently associated with significant fibro-
sis in the multivariate analysis were co-infection with
HCV, chronic elevation of AST and g-GT, cumulative
exposure to dideoxynucleosides and low serum choles-
terol. Results of the multivariate analyses (OR; 95% CI)
are displayed in Table 2.
Factors associated with significant fibrosis predicted by
FT alone were age 1.04 [1.00-1.08]), HCV co-infection
(3.77 [1.77-8.01]), chronic elevation of ALT (3.47 [1.76-
6.70]), AST (4.72 [2.25-9.90]) and g-GT (3.44 [1.80-6.57])
levels and cumulative exposure to certain antiretrovirals,
including stavudine (1.013 [1.00-1.03]) lopinavir (1.012
[1.00-1.02]) saquinavir (1.022 [1.01-1.04]) protease inhibi-
tors (1.004 [1.00-1.01]) were all associated with signifi-
cant fibrosis predicted by FT. HOMA-IR (1.22 [1.06-
1.41]) was the only metabolic factor associated with FT >
0.48. Factors remaining independently associated with
significant fibrosis in the multivariate analysis (OR; 95%
CI) were chronic AST and g-GT elevation as well as time
on saquinavir (Table 2).
Finally, univariate analysis showed that co-infection with
HCV (14.85 [4.75-46.47]), chronic ALT [7.10 2.34-21.54]),
AST (47.25 [10.12-220.92]), g-GT (18.61 [2.41-143.84])
Table 1 Main baseline characteristics of the study population (n = 202) by liver fibrosis stage using transient
elastography (TE)
Variable All patients Patients with
TE < 7.1 kPa
Patients with
TE ≥ 7.1 kPa
p-value
Mean age, years 47 ± 9 46.7 ± 9 49 ± 9 0.20
Male gender, n (%) 159 (79) 135 (80) 24 (73) 0.36
Caucasian Ethnicity, n (%) 190 (94) 157 (93) 33 (100) 0.87
CD4 count (cells/μl), mean ± SD 591 ± 254 591 ± 240 589 ± 323 0.57
Estimated duration of HIV infection in years, mean ± SD 13 ± 7 13 ± 7 15 ± 6 0.70
HBV co-infection, n (%) 18 (9) 13 (8) 5 (15) 0.18
HCV co-infection, n (%) 35 (17) 16 (10) 19 (58) < 0.0001
Chronic ALT elevation, n (%) 55 (27) 38 (23) 17 (52) 0.001
Chronic AST elevation, n (%) 38 (19) 19 (11) 19 (58) < 0.0001
Chronic g-GT elevation, n (%) 98 (49) 73 (43) 25 (76) 0.001
Exposure to cART, n (%) 179 (89) 148 (88) 31 (94) 0.38
months on NRTI
mean ± SD 188 ± 135 186 ± 138 199 ± 124 0.60
months on NNRTI
mean ± SD 36 ± 44 38 ± 47 32 ± 34 0.68
months on PI
mean ± SD 90 ± 114 83 ± 108 131 ± 135 0.72
Months on d-drugs
mean ± SD 32 ± 48 27 ± 44 55 ± 64 0.006
BMI (kg/m
2), mean ± SD 23.4 ± 3.0 23.2 ± 2.8 24.7 ± 3.7 0.06
HOMA-IR, mean ± SD 2.4 ± 2.3 2.1 ± 1.8 3.8 ± 4.0 0.006
Total serum cholesterol (mg/dl),
mean ± SD 203 ± 45 209 ± 45 176 ± 34 < 0.0001
P-values are given for differences between patients with TE values < 7.1 kPa (n = 169) vs. ≥ 7.1 kPa (n = 33)
cART, combination antiretroviral therapy; NRTI nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; PI, protease
inhibitors; d-drugs, stavudine, didanosine, or zalcitabine
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tease inhibitors (1.004 [1.00-1,01]) and dideoxynucleosides
(1.01 [1.00-1.02]) were associated with combined predic-
tion of significant fibrosis by TE and FT. Among meta-
bolic factors, high BMI (1.24 [1.05-1.45]), high HOMA-IR
(1.35 [1.13-1.61]) and low serum cholesterol (0.98 [0.96-
0.99]) were also associated with significant fibrosis. In the
multivariate analysis (OR; 95% CI), chronic AST and g-GT
elevation, low serum cholesterol and exposure to saquina-
vir remained independently associated with significant
fibrosis (Table 2).
Assessment of liver fibrosis at follow-up - longitudinal
study
Sixty-eight patients with HIV mono-infection had at least
one repeat TE examination (median time interval to first
examination, 21 months; range, 9-27 months) and 20 of
these 68 patients had two repeat TE examinations (median
time interval to second examination, 24 months; range,
19-26 months). When pooling the last available TE exami-
nation for each of the 68 patients, the median follow-up
time was 24 months (range, 9-27 months).
The median liver stiffness at the end of follow-up (last
examination available in each patient) was 4.9 kPa (range,
2.9-20.2 kPa; Figure 1).
The 68 patients without viral hepatitis who had at least
one repeat TE examination were not significantly different
from those with only one TE determination at baseline for
demographic characteristics, including age, gender, BMI,
ethnicity and risk behavior (data not shown).
Among 63/68 patients who had liver stiffness values <
7.1 kPa at baseline, 55 (87%) still had TE values < 7.1 kPa
at the end of follow-up, whereas 8 patients (13%) had
increased liver stiffness. Furthermore, 55/57 patients
(96.5%) with liver stiffness values < 7.1 kPa at follow-up
also had values below this threshold at baseline. Despite
these individual changes relative to the 7.1 kPa threshold,
median intra-patient liver stiffness changes at the end of
follow-up were not significantly different compared to
baseline in the 68 patients (-0.2 kPa; p = 0.20).
Discussion
The impact of cART and other risk factors on the devel-
opment of liver fibrosis in patients infected with HIV has
been subject to controversial debate over the past years.
Several studies indicate that long-term cART may worsen
liver fibrosis in patients with HIV/HCV co-infection and
that this effect is mostly seen with NRTIs. However,
effective control of HIV, especially through the introduc-
tion of PIs has recently been shown to be associated with
slower liver fibrosis progression in patients with HIV/
HCV co-infection who underwent paired liver biopsies
[6]. Moreover, little is known about risk factors in
patients without hepatitis co-infection and few data exist
on liver-related long-term complications of cART [3].
In our prospective study of HIV infected individuals,
mostly without hepatitis co-infection (76% of all
patients), elevated ALT, AST and g-GT levels were
observed in 19%, 8% and 45.5% of those without viral
hepatitis, suggestive of the presence of cART-related
Table 2 Factors associated with significant fibrosis according to TE (≥ 7.1 kPa), Fibrotest (> 0.48) and TE and Fibrotest
combined
TE F ≥ 2F T F ≥ 2 TE + FT F ≥ 2
Variable Multivariate analysis
OR (95% CI)
p-value Multivariate analysis
OR (95% CI)
p-value Multivariate analysis
OR (95% CI)
p-value
HCV-RNA positive 7.29 (1.95-27.34) 0.003
Chronic AST elevation 6.58 (1.30-33.25) 0.023 2.72 (1.18-6.27) 0.019 137.04 (9.57-1961.89) < 0.0001
Chronic GGT elevation 5.17 (1.56-17.08) 0.007 2.69 (1.30-5.57) 0.008 17.92 (1.52-210.98) 0.022
Total serum cholesterol 0.98 (0.96-0.99) 0.001 0.96 (0.93-0.99) 0.004
Cumulative d-drug exposure (in months) 1.01 (1.00-1.02) 0.035
Saquinavir 1.02 (1.00-1.03) 0.016 1.03 (1.00-1.06) 0.046
Data of the multivariate analysis are shown
TE, transient elastography; FT, Fibrotest; F ≥ 2, significant liver fibrosis; d-drug exposure, exposure to dideoxynucleosides
TE Baseline TE Follow-up
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Figure 1 Box plots of median liver stiffness (TE) values at
baseline and follow-up in 68 patients with HIV mono-infection
(p = 0.20). All data were log10-transformed. The top and bottom of
each box represent the first and third quartiles respectively. The
middle line represents the median. Pooled follow-up TE values are
shown for the last available TE examination in each patient. Median
follow-up time was 24 months (range, 9-27 months).
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one patient fulfilled the Hy’s rule criteria (ALT > 3xULN
and total bilirubin > 2xULN) [23]. Despite there being no
generally accepted definition of drug-induced hepatotoxi-
city, elevations of liver transaminases (ALT and AST) are
currently considered as the best indicator [5,24].
When using TE for fibrosis assessment, 16% and 5% of
patients were predicted to have significant liver fibrosis
and cirrhosis, respectively. Interestingly, this was not
exclusively attributable to HCV co-infection, as 42% and
30% of patients with liver stiffness suggestive of significant
fibrosis and cirrhosis were indeed HCV RNA negative.
Recently, Castera and co-workers have proposed an
algorithm for non-invasive fibrosis assessment that
includes a combination of TE and FT (Bordeaux algo-
rithm). When combining the two modalities, the presence
or absence of significant liver fibrosis and cirrhosis was
predicted with an accuracy of 87.7% and 95.7%, respec-
tively [22].
When we applied the above-mentioned criteria to our
data, only 8% and 3% of our patients had significant liver
fibrosis or cirrhosis. Moreover, in patients with HIV
mono-infection, the proportion of patients with signifi-
cant fibrosis and cirrhosis was even smaller (3% and
0.6%, respectively).
Thus, despite a high prevalence of chronic elevated ALT,
AST or g-GT levels, there was only evidence for liver
fibrosis in a small proportion of HIV mono-infected
patients. It should be noted however, that the Bordeaux
algorithm has not yet been validated in HIV-infected indi-
viduals with or without HCV co-infection.
In a longitudinal analysis, liver stiffness values did not
differ significantly over a median follow-up time of 24
months in patients with HIV mono-infection, indicating
that patients on cART may not be at risk of progressive
liver disease. However, the rather short follow-up period
may impose a latency bias on this observation as the actual
mean rate of liver fibrosis progression within one year has
been estimated to be as low as 0.085-0.120 for fibrosis
stages derived according to the METAVIR scoring system
in patients with chronic HCV infection [25] and it may be
even lower in patients with drug-induced fibrosis or
steatohepatitis.
Overall, in patients in whom liver fibrosis was predicted
by TE, factors independently associated with significant
fibrosis included HCV-coinfection, chronic AST and g-
GT elevation as well as exposure to dideoxynucleosides
and these results are in line with previous observations
[8,19]. With regard to cART-related hepatotoxicity, sev-
eral specific antiretroviral agents such as nevirapine,
zidovudine, stavudine, and other nucleoside analogs have
been associated with liver fibrosis progression, especially
in patients with HIV/HCV co-infection [8,26,27]. Nevira-
pine in particular has been associated with ALT and g-
GT elevation and this may account for the high preva-
lence of chronic g-GT elevation in our study as almost
half of those with g-GT elevation were taking nevirapine
at the time. This may also explain the higher percentage
of significant liver fibrosis predicted by Fibrotest that
combines the results of five blood serum tests, including
g-GT.
The potentially hepatotoxic effect of dideoxynucleo-
side-induced mitochondrial toxicity has been discussed
previously [28,29]. The reduction of mitochondrial beta-
oxidation of fatty acids may lead to hepatic steatosis,
which, over time, can lead to chronic inflammation and
liver fibrosis [30,31]. It must be noted, however, that
dideoxynucleosides have been widely replaced by newer
NRTIs with superior liver safety profiles and the use of
dideoxynucleosides is rapidly diminishing. This may also
explain why there was no increase in liver fibrosis
observed in our longitudinal study. Moreover, when
using both TE and FT, cumulative time on dideoxynu-
cleosides was only associated with significant fibrosis in
the univariate analysis.
While liver steatosis and steatohepatitis may develop as
a direct consequence of NRTI-toxicity, these conditions
can also be associated with cART-related metabolic dis-
orders, including hyperglycemia, insulin resistance, dysli-
pidemia, and obesity. Indeed, high HOMA-IR and BMI
were associated with predicted liver fibrosis when
assessed by TE and/or FT. However, their impact did not
remain significant in the multivariate models.
In several studies, excessive alcohol use was also shown
to be associated with liver fibrosis in the HIV population
[8,32]. In the present study, we excluded patients with
alcohol abuse (more than 2 standard drinks in men/one
standard drink in women) in order to minimize the alco-
hol-related impact on liver fibrosis. Indeed, alcohol con-
sumption below this threshold was not associated with
increased liver stiffness in this study.
A limitation of the present study is the lack of fibrosis
assessment by liver biopsy. H o w e v e r ,t h er o l eo fl i v e r
biopsy as “gold-standard” is subject to increasing debate,
owing to possible side effects as well as frequently occur-
ring sampling errors and variability of sample interpreta-
tion [33]. Furthermore, liver biopsy is rarely
recommended in patients with HIV mono-infection.
Conclusions
Taken together, our results showed that significant fibro-
sis or cirrhosis was present in a small subset of patients
with HIV mono-infection. However, no evidence was
observed for fibrosis progression over time. Chronic AST
and g-GT elevations as well as long-term dideoxynucleo-
side therapy were independent risk factors for those with
liver stiffness values ≥ 7.1 kPa and highlight the role of
drug hepatotoxicity in fibrosis development. Longer
Vermehren et al. BMC Gastroenterology 2012, 12:27
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Page 6 of 8follow-up studies may be necessary to show whether
cART-associated elevation of liver enzymes leads to
increased liver related morbidity and mortality.
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